Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LVRNA009 mRNA Vaccine in Chinese Adults
NCT05364047Phase 1Unknown
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LVRNA009 in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by AIM Vaccine Co., Ltd. Primary endpoints: Incidence of adverse events including solicited and unsolicited adverse events at 28 days and Incidence of adverse events associated with the experimental vaccine at 28 days. Status: unknown.
02
Drugs
LVRNA009
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05364047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364047.